Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of a Director.

On September14, 2017, Edgar G. Engleman notified the Board of Directors (the “Board”) of Eiger BioPharmaceuticals, Inc. (the “Company”) of his resignation as a director effective immediately. Dr.Engleman’s resignation was not the result of any disagreement or dispute with the Company on any matter relating to the Company’s operations, policies or practices.

(d) Appointment of a New Director.

On September15, 2017, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Evan Loh as a director effective immediately to fill the vacancy created by Dr.Engleman’s resignation. The Board appointed Dr.Loh to serve as a member of the Board as a Class II director for a term expiring at the Company’s 2020 Annual Meeting of Stockholders, or until his earlier death, resignation or removal or his successor is duly elected and qualified.

There is no arrangement or understanding between Dr.Loh and any other person to which Dr.Loh was appointed as a director. Dr.Loh is party to an indemnification agreement with the Company and will be eligible to participate in all non-employee director compensation plans and arrangements available to non-employee directors. Accordingly, Dr.Loh will be granted an option to purchase 25,000 shares of common stock of the Company under its 2013 Equity Incentive Plan. In addition, Dr.Loh will be eligible to receive an annual grant of an option to purchase 10,000 shares of common stock of the Company under its 2013 Equity Incentive Plan. Dr.Loh will also be eligible to receive cash compensation of $40,000 per year as a director.

About Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.